-

ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024, at 9:35 a.m. ET.

A webcast of the event will be available in the "News" section of the Company's website at https://renagadetx.com/news/. A replay of the webcast will be archived on the Company's website for 90 days following the presentation date.

About ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

ReNAgade Therapeutics—RNA Without Limits

For more information about the company, its technologies, and its leadership, visit www.renagadetx.com.

Contacts

Investor Relations:
Emily Brabbit, Argot Partners
(212) 600-1902
renagade@argotpartners.com

Media Relations:
Sarah Sutton, Argot Partners
(212) 600-1902
renagade@argotpartners.com

Industry:

ReNAgade Therapeutics

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)Chinese TraditionalChinese SimplifiedJapanese

Contacts

Investor Relations:
Emily Brabbit, Argot Partners
(212) 600-1902
renagade@argotpartners.com

Media Relations:
Sarah Sutton, Argot Partners
(212) 600-1902
renagade@argotpartners.com

More News From ReNAgade Therapeutics

CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions. The updated release reads: RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita Bisaria, Ph.D., M.B.A. Additional investment strengthens ReNAgade’s delivery platform with unique conjugation platform based on novel g...

ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland. “We are excited to highlight foundational research and development advancements at ASGCT supported by our poster pres...

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer. “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of...
Back to Newsroom